2023-06-26 02:46:01
As of this month, the withdrawal of permission for major items of Sandoz Korea, which decided to withdraw from the domestic business, has become a reality.
As Samil Pharmaceutical decides to take responsibility for the remaining central nervous system (CNS)-oriented items after withdrawal, its presence in the prescription market is expected to grow further.
data photo.
According to the pharmaceutical industry on the 26th, the Ministry of Food and Drug Safety disclosed the fact that Sandoz Korea had withdrawn its approval for major items such as cardiovascular drugs Tarek, Kotarek, and Genepri.
Previously, Sandoz Korea decided to withdraw from the domestic business as of June 30. This is the effect of changing the business model in the Korean market after being spun off as an independent corporation at the end of last year.
It is interpreted that the company is going through the process of withdrawing approval for major cardiovascular drugs in line with the withdrawal time.
Among them, as Sandoz Korea’s withdrawal became a reality, Samil Pharm, which received more than the remaining medicines, is attracting attention anew.
Cardiovascular drugs are withdrawn from the domestic market, but central nervous system (CNS) drugs such as antidepressants Mitrax, Sandos escitalopram, Sandosparoxetine, Sandos sertraline, schizophrenia treatment Sandos olazapine, and insomnia treatment Sandos zolpidem This is because Samil Pharmaceutical decided to take over.
Recently, in the case of Samil Pharmaceutical, it is attracting attention by developing sales and marketing of major ophthalmology drugs, and as it took over Sandoz’s items, its influence in the prescription market has grown even more.
In fact, early this year, Samil Pharmaceutical launched ‘Reba-K (Rebamipide)’, an eye drop for treating dry eye syndrome, while taking charge of the domestic sales of ‘Amelibuju (ranibizumab)’ developed by Samsung Bioepis. ‧Influence in the medical market has grown further.
In the case of Levakey eye drops, it is expected that it will replace the market occupied by hyaluronic acid eye drops amid the government’s recent promotion of reimbursement reevaluation.
In addition, it is expected to solidify its image as a professional pharmaceutical company in the ophthalmology and CNS prescription market by taking over the business of Sandoz’s CNS-type drugs.
A domestic executive who requested anonymity said, “Samil Pharmaceutical is active in the ophthalmology market to the extent that it has formed a specialized sales organization to take over the business rights of Samsung Bioepis Ameliebu.” It is expected that the image of pharmaceutical companies in the field will be further strengthened.”
1687748478
#Notice #expansion #CNS #sales #force #Samil #Pharmaceutical #Sandoz #products